Arthur He
Stock Analyst at HC Wainwright & Co.
(2.16)
# 2,661
Out of 4,944 analysts
61
Total ratings
47.46%
Success rate
-7.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LVTX LAVA Therapeutics | Maintains: Neutral | $1.5 → $1.24 | $1.53 | -18.95% | 11 | Aug 5, 2025 | |
| AUPH Aurinia Pharmaceuticals | Assumes: Buy | $17 | $12.30 | +38.21% | 1 | Jul 30, 2025 | |
| ADAP Adaptimmune Therapeutics | Downgrades: Neutral | n/a | $0.07 | - | 7 | Jul 29, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $6.5 → $120 | $25.77 | +365.66% | 4 | Jun 24, 2025 | |
| SLDB Solid Biosciences | Reiterates: Buy | $20 | $6.22 | +221.54% | 10 | Jun 17, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $75 → $85 | $21.41 | +297.01% | 2 | Jun 2, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.72 | - | 8 | May 20, 2025 | |
| ADAG Adagene | Reiterates: Buy | $8 | $1.98 | +303.10% | 10 | Apr 3, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $0.37 | - | 8 | Mar 31, 2025 |
LAVA Therapeutics
Aug 5, 2025
Maintains: Neutral
Price Target: $1.5 → $1.24
Current: $1.53
Upside: -18.95%
Aurinia Pharmaceuticals
Jul 30, 2025
Assumes: Buy
Price Target: $17
Current: $12.30
Upside: +38.21%
Adaptimmune Therapeutics
Jul 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.07
Upside: -
Nektar Therapeutics
Jun 24, 2025
Maintains: Buy
Price Target: $6.5 → $120
Current: $25.77
Upside: +365.66%
Solid Biosciences
Jun 17, 2025
Reiterates: Buy
Price Target: $20
Current: $6.22
Upside: +221.54%
Vera Therapeutics
Jun 2, 2025
Maintains: Buy
Price Target: $75 → $85
Current: $21.41
Upside: +297.01%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.72
Upside: -
Adagene
Apr 3, 2025
Reiterates: Buy
Price Target: $8
Current: $1.98
Upside: +303.10%
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.37
Upside: -